| [1] |
Topalian SL, Drake CG, Pardoll DM, et al. Immune checkpoint blockade:a common denominator approach to cancer therapy[J].Cancer Cell,2015,27(4):450-461.
|
| [2] |
Jena B,Moyes JS,Huls H,et al.Driving CAR-based T-cell therapy to success[J].Curr Hematol Malig Rep,2014,9(1):50-56.
|
| [3] |
Rosenberg SA. Raising the bar: the curative potential of human caner immunotherapy[J].Sci Transl Med,2012,4(127):844-844.
|
| [4] |
Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4,PD-1/PD-L1,or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment[J].J Immunother Cancer,2014,2(1):1-14.
|
| [5] |
Vécsei L, Szalárdy L, Fülop F, et al. Kynurenines in the CNS:recent advances and new questions[J].Nat Rev Drug Discov,2013,12(1):64-82.
|
| [6] |
Richard DM,Dawes MA,Mathias CW,et al.L-Tryptophan:basic metabolic functions,behavioral research and therapeutic indications[J].Int J Tryptophan Res,2009,2(2):45-60.
|
| [7] |
Beadle GW,Mitchell HK,Nyc JF.Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by neurospora[J].Proc Natl Acad of Sci U S A,1947,33(6):155-158.
|
| [8] |
Dounay AB,Tuttle JB,Verhoest PR.Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway[J].J Med Chem,2015,58(22):8762-8782.
|
| [9] |
Barth H,Raghuraman S.Persistent infectious diseases say -IDO.Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy[J].Crit Rev Microbiol,2014,40(4):360-368.
|
| [10] |
Théate I,van Baren N,Pilotte L,et al.Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues[J].Cancer Immunol Res,2015,3(2):161-172.
|
| [11] |
Godin-Ethier J,Hanafi LA,Piccirillo CA,et al.Indoleamine 2,3-dioxygenase expression in human cancers:clinical and immunologic perspectives[J].Clin Cancer Res,2011,17(22):6985-6991.
|
| [12] |
Li M,Bolduc AR,Hoda MN,et al.The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma[J].J Immunother Cancer,2014,2(1):1-13.
|
| [13] |
Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase[J].Proc Natl Acad Sci U S A,2012,109(7):2497-2502.
|
| [14] |
Ball HJ,Sanchez-Perez A,Weiser S,et al.Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice[J].Gene,2007,396(1):203-213.
|
| [15] |
van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan[J].Cancer Immunol Res,2015,3(9):978-985.
|
| [16] |
Munn DH,Sharma MD,Baban B,et al.GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase[J].Immunity,2005,22(5):633-642.
|
| [17] |
Metz R,Rust S,Duhadaway JB,et al.IDO inhibits a tryptophan sufficiency signal that stimulates mTOR:a novel IDO effector pathway targeted by D-1-methyl-tryptophan[J].Oncoimmunology,2012,1(9):1460-1468.
|
| [18] |
Munn DH,Mellor AL.Indoleamine 2,3 dioxygenase and metabolic control of immune responses[J].Trends Immunol,2013,34(3):137-143.
|
| [19] |
Qian S,Zhang M,Chen Q,et al.IDO as a drug target for cancer immunotherapy:recent developments in IDO inhibitors discovery[J].RSC Adv,2016,6(9):7575-7581.
|
| [20] |
van Baren N, Van den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan[J].Cancer Immunol Res,2015,3(9):978-985.
|
| [21] |
Sakamuro D,Elliott KJ,Wechslerreya R,et al.BIN1 is a novel MYC-interacting protein with features of a tumour suppressor[J].Nat Genet,1996,14(1):69-77.
|
| [22] |
Jia Y,Wang H,Wang Y,et al.Low expression of Bin1,along with high expression of IDO in tumor tissue and draining lymph nodes,are predictors of poor prognosis for esophageal squamous cell cancer patients[J].Int J Cancer,2015,137(5):1095-1106.
|
| [23] |
Muller AJ, Duhadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase,an immunoregulatory target of the cancer suppression gene Bin1,potentiates cancer chemotherapy[J].Nat Med,2005,11(3):312-319.
|
| [24] |
Rohrig UF,Majjigapu SR,Vogel P,et al.Challenges in the discovery of indoleamine 2,3-dioxygenase 1(IDO1)inhibitors[J].J Med Chem,2015,58(24):9421-9437.
|
| [25] |
Soliman HH,Minton SE,Han HS,et al.A phase I study of indoximod in patients with advanced malignancies[J].Oncotarget,2016,7(16):22928-22938.
|
| [26] |
Sugimoto H, Oda S, Otsuki T, et al. Crystal structure of human indoleamine 2,3-dioxygenase:catalytic mechanism of O2 incorporation by a heme-containing dioxygenase[J].Proc Natl Acad Sci U S A,2006,103(8):2611-2616.
|
| [27] |
Tojo S,Kohno T,Tanaka T,et al.Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors[J].ACS Med Chem Lett,2014,5(10):1119-1123.
|
| [28] |
Mautino MR,Kumar S,Jaipuri FA,et al.Imidazole derivatives as IDO inhibitors:IN,2011056652 A1[P].2011-05-12[2016-07-17] .
|
| [29] |
Mautino MR,Kumar S,Waldo J,et al.Fused imidazole derivatives as IDO inhibitors:IN,2012142237 A1[P].2012-10-18[2016-07-17] .
|
| [30] |
Mautino MR,Jaipuri FA,Waldo J,et al.Abstract 491:NLG919,a novel indoleamine-2,3-dioxygenase(IDO)-pathway inhibitor drug candidate for cancer therapy[J].Cancer Res,2013,73(8):491-491.
|
| [31] |
Nayak A,Hao Z,Sadek R,et al.Phase 1a study of the safety,pharmacokinetics,and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors[J].Eur J Cancer,2015,51(1):S69-S69.
|
| [32] |
Rahrig UF, Awad L, Grosdidier A, et al. Rational design of indoleamine 2,3-dioxygenase inhibitors[J].J Med Chem,2010,53(3):1172-1189.
|
| [33] |
Huang Q,Zheng M,Yang S,et al.Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase(IDO)inhibitors[J].Eur J Med Chem,2011,46(11):5680-5687.
|
| [34] |
Rohrig UF,Majjigapu SR,Grosdidier A,et al.Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition[J].J Med Chem,2012,55(11):5270-5290.
|
| [35] |
Boyall D,Davis C,Dodd J,et al,Compounds useful as inhibitors of indoleamine 2,3-dioxygenase:IN,2014081689 A1[P].2014-05-30[2016-07-17] .
|
| [36] |
Yue EW,Douty B,Wayland B,et al.Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model[J].J Med Chem,2009,52(52):7364-7367.
|
| [37] |
Combs AP, Yue EW, Sparks RB, et al, 1, 2, 5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase:IN,2010005958 A1[P].2010-01-14[2016-07-17] .
|
| [38] |
Gangadhar TC,Hamid O,Smith DC,et al.Preliminary results from a Phase I/II study of epacadostat(incb024360)in combination with pembrolizumab in patients with selected advanced cancers[J].J Immunothe Cancer,2015,3(S2):1-2.
|
| [39] |
Paul S,Roy A,Deka SJ,et al.Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1[J].Eur J Med Chem,2016,121(10):364-375.
|
| [40] |
Jaen JC,Osipov M,Powers JP,et al.Immunoregulatory agents:IN,2015188085 A1[P].2015-12-10[2016-07-17] .
|
| [41] |
Beck HP,Jaen JC,Osipov M,et al.Immunoregulatory agents:IN,2016073774 A2[P].2016-05-12[2016-07-17] .
|
| [42] |
Beck HP,Jaen JC,Osipov M,et al.Immunoregulatory agents:IN,2016073770 A1[P].2016-05-12[2016-07-17] .
|
| [43] |
Beck HP,Jaen JC,Osipov M,et al.Immunoregulatory agents:IN,2016073738 A2[P].2016-05-12[2016-07-17] .
|
| [44] |
Cheng MF, Hung MS, Song JS, et al. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3403-3406.
|
| [45] |
Lin SY,Yeh TK,Kuo CC,et al.Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy[J].J Med Chem,2016,59(1):419-430.
|
| [46] |
Banergee M,Middya S,Shrivastava R,et al.Aminonitriles as kynurenine pathway inhibitors:IN,2014141110 A2[P].2014-09-18[2016-07-17] .
|
| [47] |
Banergee M,Middya S,Shrivastava R,et al.Inhibitors of the kynurenine pathway:IN,2014186035 A1[P].2014-11-20[2016-07-17] .
|
| [48] |
Middya S, Yadav DB, Shrivastava R, et al, Novel iminonitrile derivatives:IN,2016027241 A1[P].2016-02-25[2016-07-17] .
|
| [49] |
Cowley P, Wise A. Inhibitors of trytophan 2, 3-dioxygenase or indoleamine 2,3-dioxygenase:IN,2016071283 A1[P].2016-05-12[2016-07-17] .
|
| [50] |
Cowley P,Wise A.Pharmaceutical compound:IN,2016071293 A2[P].2016-05-12[2016-07-17] .
|
| [51] |
Cowley P,Wise A.Pharmaceutical compound:IN,2016026772 A1[P].2016-02-25[2016-07-17] .
|
| [52] |
Cowley P,Wise A.Indole derivatives for use in medicine:IN,2015150097 A1[P].2015-10-08[2016-07-17] .
|
| [53] |
Cowley P,Wise A.Pharmaceutical compound:IN,2015082499 A2[P].2015-06-11[2016-07-17] .
|
百度学术
下载:
